Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Preferred products for long- and short-acting colony-stimulating factors

December 30, 2020

​Independence is constantly evaluating our policies and industry trends to identify opportunities to make specialty drugs more affordable without limiting members' access to life-saving medications. As a result, Independence is changing how we manage the colony-stimulating factors (CSFs) drug class.

Effective April 1, 2021, Independence will designate the following CSF drugs as preferred products:

  • Long-acting CSFs
    • Fulphila® (pegfilgrastim-jmdb)
    • Neulasta® (pegfilgrastim)
    • Udenyca® (pegfilgrastim-cbqv)
  • Short-acting CSFs
    • Granix® (tbo-filgrastim)
    • Zarxio® (filgrastim-sndz)

How this affects your patients

To preserve member continuity of care, Independence will continue to cover all preferred and non-preferred CSFs for members who are currently receiving these products. This means that members who are currently receiving a non-preferred filgrastim or pegfilgrastim product (e.g., Neupogen®, Nivestym®, Nyvepria®, Ziextenzo®) will not be required to transition to a preferred product.

However, due to new requirements that go into effect for all members on January 1, 2021, all requests for Neupogen and Nivestym must be reviewed for precertification approval from Independence.

As of April 1, 2021, all new requests for long-acting and short-acting CSFs will only be approved for the preferred products listed above, unless the member has a demonstrated intolerance or contraindication to the preferred products.

Updated policies

The Independence medical policies on pegfilgrastim will be updated to reflect new coverage criteria for preferred products. New Independence medical policies on filgrastim are in development. These policies will be posted as Notifications on the Medical and Claim Payment Policy Portal on December 31, 2020, and will go into effect April 1, 2021.

Commercial

  • #08.01.32d: Pegfilgrastim (Neulasta®) and related biosimilars
  • #08.01.73: Filgrastim (Neupogen®) and related biosimilars, and tbo-filgrastim (Granix®)

Medicare Advantage

  • #MA08.082d: Pegfilgrastim (Neulasta®) and related biosimilars
  • #MA08.130: Filgrastim (Neupogen®) and related biosimilars, and tbo-filgrastim (Granix®)

Independence will continue to investigate opportunities to establish preferred products that ensure value and access to our customers.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.